Keywords: Actelion, Asahi, Fasudil, Almorexant, Insomnia, rho kinase inhibitor, Licensing dispute

Negative outcome in arbitration with Asahi will cost Actelion $91 million; and bad news emerges with insomnia drug

Article | 23 December 2009

Print This

Swiss biotoechnology firm Actelion has received a negative ruling in its arbitration proceeding in California, USA, between one of its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in